Gunning J
Drugs. 1986;31 Suppl 2:14-7. doi: 10.2165/00003495-198600312-00004.
60 hospitalized patients with pelvic inflammatory disease entered a randomised study to compare the therapeutic efficacy and tolerability of parenteral sulbactam/ampicillin with that of clindamycin/gentamicin. All 49 pathogens isolated at entry from 21 evaluable patients in the sulbactam/ampicillin group were eradicated. 34 out of 35 pathogens isolated from 18 evaluable patients in the clindamycin/gentamicin group were eradicated. All pathogens resistant to ampicillin in vitro were eradicated. The bacteriological, clinical and overall responses for the sulbactam/ampicillin group were 100%, 85.7% and 85.7%, respectively, compared with 97.1%, 94.4% and 94.4%, respectively, for the clindamycin/gentamicin group. The sulbactam/ampicillin combination was well tolerated.
60例盆腔炎住院患者进入一项随机研究，以比较注射用舒巴坦/氨苄西林与克林霉素/庆大霉素的治疗效果和耐受性。舒巴坦/氨苄西林组21例可评估患者入院时分离出的49种病原体全部被清除。克林霉素/庆大霉素组18例可评估患者分离出的35种病原体中有34种被清除。所有对氨苄西林体外耐药的病原体均被清除。舒巴坦/氨苄西林组的细菌学、临床和总体反应率分别为100%、85.7%和85.7%，而克林霉素/庆大霉素组分别为97.1%、94.4%和94.4%。舒巴坦/氨苄西林组合耐受性良好。
